A target product profile, commonly called a TPP, is a planning document that spells out what a new medicine, vaccine, or diagnostic should look like before it reaches patients. It defines the desired safety, efficacy, dosing, and accessibility characteristics of a product and serves as the strategic backbone of therapeutic development from early research through regulatory approval and market access. Despite its central role, the TPP remains underused by many drug developers, even though properly implemented profiles help align expectations between sponsors and regulators and reduce the risk of costly late-stage failures.
What a TPP Actually Contains
Think of a TPP as a wish list with teeth. Rather than vaguely hoping a drug will be “safe and effective,” the TPP forces a development team to define, in concrete terms, what the product should achieve and for whom. A regulatory TPP is typically organized to mirror the key sections of a drug label: indication, target population, dosing and administration, mechanism of action, efficacy claims, safety and tolerability profile, and contraindications.1ScienceDirect (Academic Press). Chapter 5 – Target Product Profile and Clinical Development Plan Each of these categories includes both a “minimum acceptable” threshold and an “optimal” or aspirational target. A minimum threshold might state that the drug must reduce symptoms by at least 30 percent compared to placebo; the optimal column might aim for 50 percent or more.
An abbreviated version of the TPP is often created for commercial and business audiences. This shorter document strips away some clinical granularity and focuses on what matters for market positioning, including how the product compares to existing therapies and how its net value will be calculated.1ScienceDirect (Academic Press). Chapter 5 – Target Product Profile and Clinical Development Plan The point is that these are not separate efforts; the commercial profile flows from the regulatory one, and both trace back to the same set of cross-functional discussions that gave the TPP its shape.
The TPP is not a static document. It evolves as clinical data come in, as competitive landscapes shift, and as regulators provide feedback. A Phase I safety signal might force a revision to the tolerability section. A competitor’s approval might change the comparator the TPP benchmarks against. The development team revisits the TPP at each major decision point, using it as a living reference rather than a shelf document.
How TPPs Steer Regulatory Conversations
One of the most practical functions of a TPP is giving development teams a structured way to talk to regulatory agencies. The U.S. Food and Drug Administration has long encouraged sponsors to use TPPs as a communication tool, particularly during pre-IND meetings, which happen before a drug enters human testing for the first time. Despite this encouragement, many sponsors still show up without one.2PubMed Central. Regulatory watch: The target product profile as a tool for regulatory communication: advantageous but underused
The value of bringing a TPP to a regulatory meeting is straightforward: it turns a vague conversation into a specific one. Instead of asking the FDA “what do you think of our drug concept,” a sponsor can present a document that says “we intend to develop this product for this population, with this dosing, aiming for this efficacy bar, and we believe these safety risks are acceptable in context.” The agency can then agree, push back on specific assumptions, or flag issues the sponsor hasn’t considered. That kind of early alignment can prevent years of wasted effort. A team that discovers in Phase III that the FDA had different expectations for the primary endpoint has already burned through hundreds of millions of dollars.
This is especially true for products entering competitive therapeutic areas. If three approved drugs already treat a condition, the FDA will want to understand how the new product is differentiated. A TPP that explicitly addresses differentiation against existing therapies makes a much stronger case than a development plan that ignores the competitive context entirely.
Why Patient Perspectives Matter in TPP Design
A TPP built purely by scientists, regulators, and commercial strategists can miss what patients actually care about. Research has identified five focus areas where patient perspectives are fundamental to getting the TPP right: the target population, the unmet need, dosing frequency and route of administration, efficacy endpoints, and the acceptability of benefit-risk trade-offs.3PubMed Central. Incorporating Patient Input into the Target Product Profile
Consider dosing. A development team might assume that a daily oral pill is the ideal form factor. But for certain patient populations, that assumption can be wrong. People with opioid use disorder, for instance, may have chaotic daily routines that make daily dosing unreliable; a long-acting injectable given monthly at a clinic could be far more practical. People with conditions that affect swallowing may need a liquid formulation or a patch. These are not abstract considerations. They determine whether the product, once approved, actually gets used as intended.
Efficacy endpoints are another area where patients and researchers often diverge. A clinical trial might measure tumor shrinkage because it is easy to quantify on imaging. But if patients care more about fatigue, pain, or the ability to keep working, a TPP that ignores those patient-reported outcomes misses part of the picture. Increasingly, regulators are interested in seeing patient-reported endpoints alongside traditional clinical measures, and embedding those expectations in the TPP from the start shapes the entire trial design.
Benefit-risk trade-offs are perhaps the starkest example. For a life-threatening cancer with no alternatives, patients may accept significant side effects. For a chronic condition with several treatment options, the tolerance for side effects is much lower. These trade-offs should be defined in the TPP, and patients are the best source for understanding where the threshold lies.
Building the Case for Reimbursement Early
Regulatory approval is only half the battle. A drug that wins FDA approval but cannot secure reimbursement from health insurers or health technology assessment (HTA) bodies is, for practical purposes, inaccessible to most patients. This is where the TPP’s role extends well beyond clinical development.
Research into how pharmaceutical companies handle HTA considerations shows that all companies studied incorporated HTA requirements into their TPP development, but the timing and process varied considerably.4PubMed Central. Challenges and Opportunities for Companies to Build HTA/Payer Perspectives Into Drug Development Through the Use of a Dynamic Target Product Profile Some companies bake payer perspectives in from the earliest stages; others bolt them on later, which often means the clinical trial data do not fully address the questions that HTA agencies will ask.
HTA bodies typically want to see comparative effectiveness data: not just “does this drug work?” but “does it work better than what’s already available, and is the improvement worth the extra cost?” If the TPP doesn’t specify a head-to-head comparison against existing standard of care, the development program is likely to generate only placebo-controlled data. That data can satisfy a regulator but leave a payer unconvinced. A TPP that includes an active comparator arm from the beginning produces evidence that serves both audiences.
A well-designed TPP increases the chance that a product will be not only safe and effective, but also accessible, reimbursable, and equitably distributed.5PubMed Central. Target product profile: An essential tool to deliver differentiated, patient-centered, and reimbursable medical products to treat substance use disorders That last point, equitable distribution, is increasingly relevant as global health organizations push for products designed with resource-limited settings in mind. A product requiring ultra-cold storage may be technically excellent but impractical in regions without reliable cold chains.
TPPs in Global Health
The World Health Organization has adopted the TPP framework as a tool for steering global research and development priorities. WHO target product profiles define the characteristics required in new health products to address the greatest public health needs, covering medicines, vaccines, diagnostics, and medical equipment.6PubMed Central. WHO target product profiles to shape global research and development Unlike company-driven TPPs that focus on a specific molecule or product, WHO TPPs describe a gap in the health landscape and invite the research community to fill it.
WHO has also established a Target Product Profile Directory, a free online database of desired characteristics for health products. This directory lets researchers, manufacturers, and funders see what is needed and where, which helps coordinate investment and avoid duplication. For a small biotech company wondering whether its malaria diagnostic concept aligns with global needs, the directory provides a direct answer.
The global health context adds dimensions that a purely commercial TPP might overlook. Cost targets become central rather than aspirational. Shelf stability in tropical climates matters. Ease of use by healthcare workers with limited training is specified. These practical constraints shape product design from the outset, which is the entire philosophy behind the TPP approach: define what you need before you start building, not after you have something to sell.
COVID-19 Vaccines as a Real-World TPP Test
The COVID-19 pandemic provided a large-scale, real-time test of the TPP concept. Early in the pandemic, researchers and organizations proposed TPPs for ideal and minimally acceptable COVID-19 vaccines, specifying characteristics such as efficacy thresholds, storage requirements, number of doses, and onset of protection. As clinical trial data emerged, those TPPs served as scorecards: how well did the actual candidate vaccines stack up against what had been laid out as necessary?7PubMed Central. Target Product Profile Analysis of COVID-19 Vaccines in Phase III Clinical Trials and Beyond: An Early 2021 Perspective
The exercise was revealing. Some vaccines exceeded the TPP’s efficacy targets by a wide margin. Others met efficacy thresholds but fell short on practical criteria like cold-chain requirements. The mRNA vaccines, for example, delivered outstanding efficacy but initially required ultra-cold storage, which limited their use in low-resource settings. Viral vector and protein subunit vaccines offered easier storage but, in some cases, lower or less durable efficacy. The TPP framework made those trade-offs explicit and comparable, rather than leaving each vaccine to be evaluated in isolation.
This pandemic case study also highlighted how TPPs can evolve under pressure. As new variants emerged and real-world data on duration of protection accumulated, the characteristics that mattered shifted. What started as a focus on preventing symptomatic infection expanded to include preventing severe disease and hospitalization, reflecting a more pragmatic view of what vaccines could realistically achieve as the virus mutated.
Advanced Therapies Push the TPP Framework Further
Gene therapies and cell-based treatments present unique challenges for TPP design. A traditional small-molecule drug can be manufactured at scale, shipped globally, and stored on a pharmacy shelf. A gene therapy may involve harvesting a patient’s own cells, modifying them in a specialized lab, and re-infusing them, a process that demands entirely different criteria for manufacturing, administration, and cost.
TPPs for gene therapies aimed at curing HIV, for instance, outline both minimal and optimal characteristics for products that would allow patients to stop taking daily antiretroviral drugs permanently.8PubMed. Target product profile for cell-based and gene-based therapies to achieve a cure for HIV The minimal bar includes durable viral control without antiretrovirals, acceptable safety over the long term, and feasibility in clinical settings outside of a handful of academic medical centers. The optimal profile adds broader accessibility and lower cost, though that remains aspirational for most gene therapies today.
A similar effort for sickle cell disease gene therapies used a consensus-driven approach, bringing together a large multidisciplinary expert group to define 20 minimal and optimal criteria across categories including scope, performance and safety, manufacturing, and administration.9Molecular Therapy: Methods & Clinical Development. Consensus-driven target product profiles for curative sickle cell disease gene therapies The criteria for ex vivo products (where cells are removed, modified, and returned) differed from in vivo products (where the genetic modification happens inside the patient’s body), particularly around manufacturing and administration. That distinction matters enormously for real-world implementation: an in vivo approach that can be delivered as a single injection is a fundamentally different product from an ex vivo approach requiring weeks of cell processing at a specialized facility.
These examples show the TPP framework bending without breaking. The core logic, define what you want and set thresholds for “good enough” versus “ideal,” holds up even when the therapy is radically different from a conventional pill.
Digital Health and Artificial Intelligence
As digital health technologies gain traction, the TPP framework is being extended into territory it was not originally designed for. A systematic review of TPPs for digital health technologies found 14 existing profiles, most focused on low- and middle-income settings and communicable diseases. Only one addressed the specific requirements of an AI-powered device.10PubMed Central. Target product profiles for digital health technologies including those with artificial intelligence: a systematic review
Across these 14 TPPs, researchers catalogued 248 different characteristics and consolidated them into 33 key attributes. Some considerations that you might expect to see, such as regulatory requirements or environmental sustainability, were reported inconsistently or not at all. That inconsistency reflects how young this field is. Traditional drug TPPs have decades of refinement behind them; digital health TPPs are still figuring out what belongs on the checklist.
AI introduces particular complications. A machine-learning algorithm that diagnoses skin conditions from photos, for example, needs TPP criteria around algorithmic bias, data privacy, performance across skin tones and lighting conditions, and how the tool handles cases where its confidence is low. None of these map neatly onto the label-section structure that works for a drug. The field is in early days, and the gap between the TPP framework’s potential for digital health and its current adoption is wide.
Designing for Pediatric and Vulnerable Populations
Children are not small adults, and TPPs for pediatric products need to reflect that. The World Health Organization developed a pediatric quality target product profile tool to evaluate whether formulations on its Essential Medicines List for Children are actually age-appropriate.11PubMed Central. Assessing the Appropriateness of Formulations on the WHO Model List of Essential Medicines for Children: Development of a Paediatric Quality Target Product Profile Tool The tool combines pediatric-specific attributes, such as palatability, swallowability for different age groups, and dosing flexibility for varying body weights, with global health considerations like heat stability and minimal need for reconstitution.
The practical stakes here are easy to underestimate. A tablet designed for adults may need to be split or crushed for a young child, leading to inaccurate dosing or poor taste that causes the child to refuse the medicine. A liquid formulation might solve the taste problem but require refrigeration that isn’t available in a rural clinic. A dispersible tablet that dissolves in a small volume of water, tastes acceptable, and stays stable at tropical temperatures is a different product entirely, and the TPP is the tool that makes those requirements explicit rather than afterthoughts.
The scoring system WHO developed allows researchers to evaluate existing formulations against the pediatric TPP criteria and identify gaps. Where a gap is found, it signals a clear development need: there is a medicine on the essential medicines list that children are supposed to have access to, but the available formulation doesn’t meet their needs. That gap becomes a target for reformulation or new product development, with the TPP specifying exactly what “better” looks like.
Real-World Evidence and the Evolving TPP
One development reshaping how TPPs are constructed is the growing role of real-world evidence in regulatory decisions. Among 218 labeling expansions granted by the FDA from 2022 to 2024, real-world evidence was found in FDA documents or supporting submissions for roughly a quarter of approvals each year.12PubMed. Real-World Evidence in FDA Approvals for Labeling Expansion of Small Molecules and Biologics The real-world evidence came from 88 studies, with about half addressing both safety and efficacy. Oncology led the way, accounting for over 40 percent of the approvals that included real-world data.
For TPP design, this trend has practical implications. If a development team is planning a labeling expansion, say extending an approved cancer drug to a new tumor type, they can now consider building a real-world evidence strategy into the TPP alongside traditional clinical trial requirements. This doesn’t replace randomized trials, but it opens a complementary pathway, especially for rare diseases or populations where running a large randomized trial is impractical.
A TPP that anticipates the use of real-world evidence might specify, for example, that the development plan should include a registry study or an analysis of electronic health records to characterize the natural history of the disease. That evidence then supports the regulatory submission and, separately, provides data that payers and HTA bodies find useful for understanding how the drug performs outside of carefully controlled trial conditions.
When a TPP Gets Substance Use Disorders Right
Substance use disorders illustrate why TPP design requires more than clinical acumen. A product developed for opioid use disorder, for example, must compete not only against existing medications like methadone and buprenorphine but also against the particular barriers that this patient population faces: stigma, unstable housing, limited access to healthcare settings, and high rates of treatment dropout.
A thoughtful TPP for this space would specify safety, efficacy, usability, access, and differentiation against existing therapies, while balancing regulatory feasibility, clinical relevance, and commercial viability.5PubMed Central. Target product profile: An essential tool to deliver differentiated, patient-centered, and reimbursable medical products to treat substance use disorders Usability in this context might mean a formulation that does not require daily clinic visits or that is resistant to diversion. Access might mean a price point compatible with Medicaid reimbursement, since a large share of people with opioid use disorder are covered by public insurance. Differentiation might mean a longer duration of action or a route of administration that reduces the risk of missed doses.
The point is that a generic TPP template, filled in with pharmacological data alone, would miss most of what makes or breaks a product in this therapeutic area. The TPP has to encode an understanding of the patient’s life, the healthcare system they navigate, and the competitive alternatives they already have. That encoding happens through the cross-functional discussions that generate the TPP: clinicians, patients, commercial strategists, access experts, and regulatory scientists all contributing their piece of the picture. When those conversations happen early and honestly, the development program that follows has a much better chance of producing something that matters.